stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Operating cash flow
Xenon Pharmaceuticals Inc.'s operating cash flow for fiscal 2025 was −$279.1M, compared with −$181.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$337.5M. Over the past ten years it has ranged from −$279.1M (fiscal 2025) to −$4.7M (fiscal 2019) — the current reading is the lowest in ten years. Operating cash flow has fallen for 6 consecutive fiscal years. Xenon Pharmaceuticals Inc. ranks 575th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$279.1M | — |
| FY2024 | −$181.4M | — |
| FY2023 | −$151.1M | — |
| FY2022 | −$98.4M | — |
| FY2021 | −$69.5M | — |
| FY2020 | −$48.1M | — |
| FY2019 | −$4.7M | — |
| FY2018 | −$34.7M | — |
| FY2017 | −$28.7M | — |
| FY2016 | −$19.6M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$95.4M | — |
| Mar 2026 | −$88.9M | — |
| Dec 2025 | −$81.5M | — |
| Sep 2025 | −$71.8M | — |
| 42 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $97.5M |
| ABCL AbCellera Biologics Inc. compare | −$94.9M |
| PBLS Parabilis Medicines, Inc. compare | −$118.1M |
| TNGX Tango Therapeutics, Inc. compare | −$143.9M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$190.0M |
| IRON Disc Medicine, Inc. compare | −$197.5M |
| RLAY Relay Therapeutics, Inc. compare | −$212.2M |
| XENE Xenon Pharmaceuticals Inc. | −$337.5M |
| VKTX Viking Therapeutics, Inc. compare | −$462.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement